Johnson & Johnson announced Monday that the company has selected a lead COVID-19 vaccine candidate. The candidate is from constructs that the company has been working on since January of this year, according to a press release.
The global pharmaceutics and medical supplies company said that its goal is to provide more than 1 billion doses of the vaccine.
Human trials for the vaccine would begin by September 2020 at the latest and be available for early use authorization in early 2021, according to the press release.
Geneva Wood had contracted COVID-19 at the the Life Care Center in Kirkland, Washington, which became an early epicenter of the nation’s novel coronavirus outbreak. “Through a landmark new partnership, BARDA [Biomedical Advanced